[Featured Stock] KPM Tech Selected for Humanigen's Large-Scale COVID-19 Clinical Program at US National Institutes of Health

[Asia Economy Reporter Hyungsoo Park] KPM Tech's stock price is showing strength. The news that Humanigen, in which it has invested, has had its COVID-19 treatment selected for the U.S. National Institutes of Health (NIH) ACTIV-5 program appears to have influenced the stock price.

As of 10:42 a.m. on the 14th, KPM Tech is trading at 4,355 won, up 4.69% from the previous day.

According to foreign media, on the 13th (U.S. local time), Humanigen was selected for the NIH clinical program 'ACTIV-5 Big Effect Trial.' Humanigen is developing a COVID-19 treatment using its pipeline drug Lenzilumab.

ACTIV-5 is one of the clinical trials for discovering COVID-19 treatments. It is conducted on COVID-19 patients across 40 regions in the U.S. and includes tests comparing placebo, Remdesivir, and Lenzilumab.

Humanigen, listed on the U.S. Nasdaq, develops various new drugs using its pipeline drug Lenzilumab. It is currently conducting Phase 3 clinical trials for a COVID-19 treatment in the U.S. Earlier this year, KPM Tech and Telcon RF Pharmaceutical invested a total of 4 million dollars in Humanigen.

Dr. Anthony Fauci of NIAID explained, “The goal is to quickly identify treatments that show potential as COVID-19 therapies in clinical trials and move them into large-scale testing.”

This content was produced with the assistance of AI translation services.